• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Diseases & Conditions

  • All Diseases and Conditions

The following clinical trials are associated with All diseases and conditions.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next
  • expand A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers.
    Study Id
    D5010C00001
    Disease
    clinical pharmacodynamics, clinical pharmacokinetics
    Drug Name
    AstraZeneca Neuroscience Development Drugs
    Study Name
    D5010C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy.
    Study Id
    D5170C00001
    Disease
    Crohn's disease
    Drug Name
    AstraZeneca Gastrointestinal Development Drugs
    Study Name
    D5170C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
    Study Id
    D4280C00006
    Disease
    bacterial infection, infectious diseases
    Drug Name
    CAZ-104
    Study Name
    D4280C00006
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Perception of symptom variability in Chinese COPD patients
    Study Id
    NIS-RCN-XXX-2012/1
    Disease
    chronic obstructive pulmonary disease
    Drug Name
    non drug study (respiratory)
    Study Name
    NIS-RCN-XXX-2012/1
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease
    Study Id
    Brilinta (AZD6140)
    Disease
    coronary artery disease
    Drug Name
    AZD6140
    Study Name
    D5130L00013
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease
    Study Id
    Brilinta (AZD6140)
    Disease
    coronary artery disease
    Drug Name
    AZD6140
    Study Name
    D5130L00012
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt
    Study Id
    NIS-GEG-XXX-2012/1
    Disease
    gastroesophageal reflux disease
    Drug Name
    non drug study (gastrointestinal)
    Study Name
    NIS-GEG-XXX-2012/1
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase II, Open label, Non randomised, Non comparative, Multicentre study to assess the efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA 1 and/or BRCA2 mutation
    Study Id
    D0810C00042
    Disease
    cancer
    Drug Name
    Olaparib
    Study Name
    D0810C00042
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A open label, randomized, crossover and potential parallel, single dose study of ticagrelor 180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo platelet transfusion to determine the effects of platelet supplementation on the reversibility of platelet inhibition
    Study Id
    D5130C00079
    Disease
    blood clot
    Drug Name
    Brilinta
    Study Name
    D5130C00079
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Faslodex Specific Clinical Experience Investigation for long-term use
    Study Id
    D6997C00008
    Disease
    breast cancer, drug safety
    Drug Name
    Faslodex
    Study Name
    D6997C00008
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013